Clinical Trial Update: Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating uniform FDG-PET guided gradient dose prescription to reduce late radiation toxicity in head and neck squamous cell carcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: Radboud University Medical Center | Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 3 | Status: COMPLETED